-- Cavendish on Tuesday downgraded financial technology company Plus500 (PLUS.L) to hold from buy and increased its price target to 46.85 pounds sterling from 46.65 pounds.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Alexandre Magnani, Director, on April 17, 2026, sold 200,000 shares in Pagseguro Digital (PAGS) for $2,252,000. Following the Form 4 filing with the SEC, Magnani has control over a total of 607,390 Class A common shares of the company, with 607,390 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1712807/000129281426002435/xslF345X05/ownership.xmlPrice: $11.31, Change: $-0.01, Percent Change: -0.09%
Axsome Therapeutics' (AXSM) shares are likely facing an "attractive setup" ahead of the US Food and Drug Administration's approval decision of a label expansion of Auvelity into Alzheimer's disease agitation, Oppenheimer said in a note Tuesday.Oppenheimer said it forecasts a 20% upside with a 95% probability versus a 35% downside upon the FDA's decision, reflecting the investment firm's about $2 billion sales estimate, with a priority review for the drug backing its conviction.The investment firm noted Auvelity was originally approved for major depressive disorder in Q3 2022, and was also given breakthrough therapy designation for a potential label expansion into Alzheimer's disease agitation.Oppenheimer said it sees "distinct commercial advantages" for Auvelity, as it may "compete on clean safety, which also justifies formulary positioning and longer-term use" compared with competing Alzheimer's disease agitation drug Rexulti.Meanwhile, Auvelity is also competitively well-positioned compared with candidate drugs in development like Cobenfy, which are "far behind," the note said.Oppenheimer has an outperform rating on Axsome and a $220 price target.Price: $183.26, Change: $-5.43, Percent Change: -2.88%
US equity indexes fell, giving up intraday gains, as crude oil futures gathered momentum in midday trading on Tuesday, with investors still awaiting confirmation from Iran that it will attend the second round of peace talks in Pakistan.The Nasdaq Composite slipped 0.1% to 24,380.8, with the S&P 500 down 0.2% to 7,097.6 and the Dow Jones Industrial Average lower by 0.2% to 49,337.5. All three gauges traded higher earlier in the session amid the flow of quarterly results.President Donald Trump told CNBC on Tuesday that he expects the US and Iran to make a "great deal," referring to the proposed second round of talks in Islamabad that Iran has yet to confirm it will attend. The president added, however, that the US military is "ready" to bomb Iran if a deal is not signed by the ceasefire deadline Wednesday evening and that he does not want to extend it.West Texas Intermediate crude oil futures climbed 4.3% to $93.50, and Brent crude futures advanced 2.8% to $98.17.In company news, UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday, as the health insurance giant recorded an unexpected annual increase in its Q1 results. Shares jumped 7.6%, the top gainer on the S&P 500 and the Dow.D.R. Horton's (DHI) fiscal Q2 results came in better than expected, although the homebuilder tempered its full-year revenue outlook. Shares advanced 7.1%, among the S&P 500's outperformers.